The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

On Saturday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SUMMIT Phase 3 trial showing tirzepatide reduced ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

As far as competition goes, Eli Lilly is one of the two current leaders in the weight loss space, along with Novo Nordisk.

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Also Read: 99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly’s Detailed Phase 3 Data Shows The FDA approved tirzepatide as Mounjaro for adults with type 2 ...

Eli Lilly now ranks as the largest drugmaker in the world based on market cap. Its remarkable rise has been largely due to ...